Search clinical trials for: PF-06700841 or Placebo

Total 1160 results

Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
Pfizer

Completed

A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Healthy

Belgium
Columbia University
Pfizer

Withdrawn

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

NASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Ali Amini Harandi

Unknown

MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code) (MLC901)

Traumatic Brain Injury

Iran, Islamic Republic of
Pfizer

Completed

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Healthy Participants

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Migraine | Major Depressive Disorder

United States, Czechia, Finland, Israel, Italy, Russian Federation, Spain, Ukraine, France, Germany, Greece, Poland, United Kingdom
Pfizer

Completed

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia (IEM)

Inherited Erythromelalgia

United States
Pfizer

Completed

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

Healthy

United States
Pfizer

Completed

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Type 2 Diabetes Mellitus

United States, Canada
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Multiple Dose Study Of PF-06678552 In Healthy Subjects

Healthy

Belgium
Pfizer

Terminated

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Withdrawn

A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

Migraine
Pfizer

Completed

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Type 2 Diabetes Patients

United States
Pfizer

Completed

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Alzheimer's Disease

United States, Sweden
Pfizer

Completed

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Respiratory Tract Infections

United States
Pfizer

Completed

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Completed

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, United States, Korea, Republic of, Puerto Rico
Telavant, Inc.
Pfizer

Completed

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Genexine, Inc.

Completed

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Autoimmune Diseases

Korea, Republic of
Pfizer

Completed

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Healthy Participants

United States
Biogen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Hearing Loss, Sensorineural

United States
Biogen

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Healthy Subjects

United States
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Healthy Subjects

Belgium
Pfizer

Completed

Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions

Healthy

United States
Pfizer

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects

Healthy

Belgium
Green Cross Corporation
Korean Center for Disease Control and Prevention

Completed

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (GC1109)

Anthrax

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Creabilis SA
Aalborg University Hospital

Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Neuropathic Pain

Denmark
Hanmi Pharmaceutical Company Limited

Completed

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Healthy

United States
Juventas Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Critical Limb Ischemia

United States, India
Pfizer

Completed

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Viral Disease

United States, Spain, Brazil, Belgium
Pfizer

Completed

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Devintec Sagl
Meditrial SrL

Recruiting

Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation

Recurrent Aphthous Ulcer

Italy
Newsoara Biopharma Co., Ltd.

Unknown

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Healthy

China
Unity Biotechnology, Inc.

Terminated

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Knee Osteoarthritis

United States
JULIANA AQUINO DE MOURA

Completed

The Effect of Non-hormonal Gel Application in Women in the Menacme With Sexual Dysfunction

Sexual Dysfunction
Pfizer

Completed

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Spain, Czechia, Serbia, Singapore, Taiwan, Hungary, Ukraine, Hong Kong, Korea, Republic of, Russian Federation, Slovakia, Turkey
Akesobio Australia Pty Ltd

Completed

A Study of AK111 in Healthy Subjects

Psoriasis

New Zealand
Curadim Pharma Co., Ltd.

Unknown

A First-in-human Phase 1 Study of CP1050

Healthy Subjects

United Kingdom
GlaxoSmithKline

Completed

First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.

Pain, Inflammatory

United Kingdom

3

Subscribe